Answers are grounded in this paper and cite their sources.
The use of IPSS‐M provides a wealth of molecular information in newly diagnosed myelodysplastic syndromes (MDS) patients. Besides the prognostic implications, molecular markers will also help to choose therapeutic options and may also be informative to determine the depth of response. Duployez and Preudhomme provide a comprehensive overview of this area of research, which is particularly complex in MDS. Commentary on: Duployez et al. Monitoring molecular changes in the management of myelodysplastic syndromes. Br J Haematol 2024; 205:772‐779.
No takes yet. Share an insight, caveat, or question.
Christof Scheid (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: